Metabolomics Analysis of Mesenchymal Stem Cell (MSC) Therapy in a Phase I Clinical Trial of Septic Shock: An Exploratory Study

Metabolomics Analysis of Mesenchymal Stem Cell (MSC) Therapy in a Phase I Clinical Trial of Septic Shock: An Exploratory Study

Sepsis is the result of an uncontrolled host inflammatory response to infection that may lead to septic shock with multiorgan failure and a high mortality rate. There is an urgent need to improve early diagnosis and to find markers identifying those who will develop septic shock and certainly a need...

Full description

Bibliographic Details
Main Authors: Mohammad M. Banoei, Lauralyn A. McIntyre, Duncan J. Stewart, Shirley H. J. Mei, David Courtman, Irene Watpool, John Granton, John Marshall, Claudia dos Santos, Keith R. Walley, Kenny Schlosser, Dean A. Fergusson, Brent W. Winston, on behalf of Canadian Critical Care Trials Group (CCCTG), on behalf of Canadian Critical Care Translational Biology Group (CCCTBG)
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Metabolites
Subjects:
biomarker
mesenchymal stem cells
septic shock
clinical trial
metabolomics
cell therapy
Online Access:https://www.mdpi.com/2218-1989/13/11/1142

Similar Items

Similar Items